Alex Nowak: Hey great. Good morning everyone. David, I wanted to push a little bit more around the alternative pass. And I know you don’t want to rebuild too much of the game plan, but if I’m just hearing you correctly, it sounds like it could potentially use the European data in the PMA submission and maybe you could bypass some of the workflow that is needed for a PMA if you just were solely doing in the US?
David Fischel: It is — hi Alex, it is obviously, an important topic and an important question. I don’t want to go into great detail of that now. I don’t think it’s appropriate to do so. I think that it is obviously the MAGiC catheter is highly important product in terms of ensuring that physicians that use our technology and the patients that they treat have access to robotics and the latest generation of robotics in kind of the best fashion possible. I’m grateful that that kind of the regulators understand that importance. And we are being creative in how we’re thinking about collecting data to ensure that MAGiC is clearly kind of an efficacious and safe device. And so we’ve been fortunate to have the opportunity to explore various ideas in a collaborative fashion.
I will know more in the coming weeks. And so I believe by the next call, we’ll be in a position to be able to share much more, again, kind of our baseline path, which we are advancing and committed to is that submitting an IDE application in the near-term, but there may be opportunities for an improved timeline there that would provide MAGiC to US physicians and patients in an accelerated path.
Alex Nowak: Okay. Understood. Well, I look forward to that update there next quarter. Sounds very interesting. Maybe on utilization, if you back out some of the one-time items here with regards to, I guess, maybe not one-time, but the royalty, the catheter shortages, how is underlying usage and utilization with Niobe and Genesis going this quarter?
David Fischel: So, obviously, from a recurring revenue perspective, you see the hit because of the loss of the royalty that has nothing to do with utilization. That’s purely a kind of a dollar hit per procedure. And on the utilization side, we were hamstrung by the shortages of J&J catheters, which did impact volumes in the second quarter. They also did impact in the first quarter before that and overall, that high single-digit impact to recurring revenue, the shortage of catheters and the impact on utilization. I’d say we expect, given what we’ve seen in live the commentary we’ve received, it seems like the shortages on catheter are largely over. And so we’d expect to bounce back to more normal volumes in the third quarter. And overall, we still see utilization at Genesis accounts being higher than a Niobe accounts. And so we see kind of the benefit of new technology and what new technology brings to the marketplace. And so that has been kind of good to see.
Alex Nowak: Okay. Excellent. And then maybe just lastly, just how is the overall hospital environment in recent months? It might seem like based on the commentary, things are starting to break free a little bit. New placements and new orders are starting to flow in, maybe a little bit easier than it has been during the pandemic.
David Fischel: Yes. So I’d say it’s mix. We’re again — I think I’ve made the comment sometimes in the past that we are still a relatively smaller player in the field. And so it’s hard to take macro trends from our experience. Generally, what you described is true. We do send multiple hospitals that are engaging with us. There are definitely hospitals that are forward on projects that are kind of — that are able to move forward. We see kind of tenders in Europe that take place. And so it kind of — that overall feels good. There are definitely the counter examples where there are hospitals that are very financially pressured, and they are being very tight on any spendings or any projects. And so we see the spectrum of experiences across our hospital customers.
